An interventional study of IQOS and Cigarette in Smoking, Abdominal Aortic Aneurysm and IQOS Use, sponsored by Philip Morris Products S.A.. Completed at 13 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by Philip Morris Products S.A. (part of Philip Morris International) · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Smoking by Philip Morris International — none open to participants now, 2 under way, none of them phase 3. Smoking · Philip Morris International.
Among the 36 studies in Smoking by Philip Morris International, this one is the 24th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2018, is one of 31 with no phase, and was the 25th registered.
1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.
Browse Smoking studies →None of the 36 studies in Smoking by Philip Morris International is open now. The open studies under Smoking, anywhere →
Of the 145 Smoking studies recruiting now, 76 (52%) set no upper age limit and 51 (35%) stop at 75 or younger; 3 take children under 18; 69 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2018.
This study's enrollment of 48 is below the median of 116 across 1,167 interventional studies indexed under Smoking.
Median enrollment 87 across the 32 interventional studies, 1,097 across the 4 observational. Of the 33 that completed or were terminated, 26 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Philip Morris Products S.A., one of the names counted as Philip Morris International. Under that name alone:
Philip Morris Products S.A. is the lead sponsor of 49 studies on the registry; none are open to participants now.
1 of the studies in Smoking by Philip Morris International that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07108166Philip Morris Products S.A.Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Smoking by Philip Morris International, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the reduction of the Abdominal Aortic Aneurysm (AAA) annual growth rate in patients who switched from smoking cigarettes to using IQOS as compared to patients who continued to smoke cigarettes, and to patients who had quit smoking. The study also aimed to provide context to the scale of reduction in the growth rate, by comparing the AAA annual growth rates for continuing to smoke and switching to IQOS with the AAA annual growth rate in smokers who had stopped smoking. The study further evaluated the effects of switching to IQOS on co-morbidities observed in AAA patients that are related to smoking as well as to assess the effects on relevant Biomarkers of Potential Harm (BoPH) linked to smoking related diseases.
This was a controlled, open-label, 3-arm parallel group, multi-center study in patients diagnosed with Abdominal Aortic Aneurysm (AAA) to evaluate the AAA annual growth rate in adult smokers randomized to either continue smoking combustible cigarettes (CC) or to switch to IQOS and in adults who had stopped smoking, as a non-randomized control arm.
This was a descriptive study, designed to gain an understanding of how changes in smoking behaviors impact AAA growth rate and disease progression. Therefore, there were no formal statistical hypotheses to be tested.
Smoking patients with AAA who did not quit smoking after their AAA diagnosis, and who were not intending to quit within the next 6 months were screened for enrollment and randomization in the CC and IQOS arms if all other eligibility criteria were met.
Smoking patients with AAA who had completely stopped smoking and using any other tobacco or nicotine-containing products within 2 months of their AAA diagnosis, and were still abstinent at the time of the Screening Visit and of the Baseline Visit were screened to be enrolled in the smoking cessation (SC) arm without randomization.
General Inclusion Criteria:
Inclusion criteria specific to patients screened for enrollment and randomization to the CC or IQOS arm:
Inclusion Criteria specific to patients screened for enrollment into the SC arm:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with AAA, switching from cigarette smoking to IQOS use
Other: IQOS
Patients diagnosed with AAA, continuing to smoke cigarettes
Other: Cigarette
Patients diagnosed with AAA, who have completely stopped smoking and are not using any other tobacco or nicotine-containing product(s)
Other: Smoking Cessation
AAA patients will switch from cigarette smoking to ad libitum IQOS use, with no flavor variant restrictions.
AAA patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.
AAA patients who have completely quit smoking will continue to remain abstinent from smoking cigarettes or using any tobacco or nicotine-containing product(s)
AAA Annual Growth Rate Over Time
AAA annual growth rate will be measured in AAA patients who switch from smoking cigarettes to using IQOS, and AAA patients who continue to smoke CC, as compared to AAA patients who had stopped smoking. Maximum minor-axis AAA diameter in mm will be measured. Annual growth rate will be calculated by annualizing the slope of the linear regression over the available diameter measurements.
Time frame: At 6-month intervals from baseline to V8 (month 36)
Percentage of Subjects Without Open Surgical AAA Treatment or AAA Endovascular Repair Over Time
This outcome measured the percentage of subjects without surgery or endovascular repair over time in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking.
Time frame: From time of AAA diagnosis (prior to study participation) until V8 (month 36), a time frame of up to 7 years
Percentage of Subjects Without Open Surgical AAA Treatment or AAA Rupture Over Time
This outcome measured the percentage of subjects without surgery or AAA rupture over time in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking.
Time frame: From time of AAA diagnosis (prior to study participation) until V8 (month 36), a time frame of up to 7 years
Incidence of Open Surgical AAA Treatment or AAA Endovascular Repair and AAA Rupture
The incidence of open surgical AAA treatment or AAA endovascular repair and AAA rupture will be measured in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue to smoke CC and AAA patients who had stopped smoking. Incidence rate will be calculated annually.
Time frame: From baseline to V8 (month 36)
Incidence of AAA Growth Above 5 mm Within 6 Months
Incidence of AAA growth above 5 mm within 6 months will be measured in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking. Incidence rate will be calculated annually by counting the number of patients with an increase in maximum minor-axis AAA diameter of more than 5 mm within 6 months.
Time frame: At 6-month intervals from baseline to V8 (month 36)
AAA Patients With an Overall Maximum Minor-axis AAA Diameter of >55mm in Male Patients and >50mm in Female Patients
The number of AAA patients with an overall maximum minor-axis AAA diameter \>55mm in male AAA patients and \>50mm in female AAA patients will be counted in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking. (Note that the 95% CI is calculated by exact method (Clopper-Pearson) and refers to CI for a proportion).
Time frame: From baseline to V8 (month 36)
Systolic Blood Pressure
This cardiovascular BoPH (systolic blood pressure) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
Time frame: From V1 (screening) to V8 (month 36)
Urinary Nicotine Equivalents (NEQ)
To measure nicotine exposure over time in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC, and AAA patients who had stopped smoking. (NEQ adjusted for creatinine (mg/g creat)).
Time frame: From baseline to V8 (month 36)
Diastolic Blood Pressure
This cardiovascular BoPH (diastolic blood pressure) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
Time frame: From V1 (screening) to V8 (month 36)
Body Weight
This cardiovascular BoPH (body weight) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
Time frame: From V1 (screening) to V8 (month 36)
Waist Circumference
This cardiovascular BoPH (waist circumference) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
Time frame: From V1 (screening) to V8 (month 36)
Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL)
This biomarker of exposure to a tobacco smoke constituent will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
Time frame: From baseline to V8 (month 36)
Total N-nitrosonornicotine (Total NNN)
This biomarker of exposure to a tobacco smoke constituent will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
Time frame: From baseline to V8 (month 36)
2-cyanoethylmercapturic Acid (2-CyEMA)
This biomarker of exposure to a tobacco smoke constituent will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
Time frame: From baseline to V8 (month 36)
| Milestone | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| Started | 16 | 16 | 16 |
| Completed | 16 | 16 | 16 |
| Not completed | 0 | 0 | 0 |
| Milestone | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| Started | 16 | 16 | 16 |
| Completed | 16 | 16 | 15 |
| Not completed | 0 | 0 | 1 |
| Milestone | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| Started | 16 | 16 | 15 |
| Completed | 16 | 14 | 14 |
| Not completed | 0 | 2 | 1 |
| Milestone | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| Started | 16 | 14 | 14 |
| Completed | 14 | 13 | 14 |
| Not completed | 2 | 1 | 0 |
| Milestone | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| Started | 14 | 13 | 14 |
| Completed | 14 | 12 | 14 |
| Not completed | 0 | 1 | 0 |
| Milestone | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| Started | 14 | 12 | 14 |
| Completed | 13 | 11 | 14 |
| Not completed | 1 | 1 | 0 |
AAA annual growth rate will be measured in AAA patients who switch from smoking cigarettes to using IQOS, and AAA patients who continue to smoke CC, as compared to AAA patients who had stopped smoking. Maximum minor-axis AAA diameter in mm will be measured. Annual growth rate will be calculated by annualizing the slope of the linear regression over the available diameter measurements.
| (mm/year) | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| AAA Annual Growth Rate Over Time | 1.80 (0.94 to 2.66) | 1.87 (1.33 to 2.40) | 1.27 (0.84 to 1.70) |
This outcome measured the percentage of subjects without surgery or endovascular repair over time in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking.
| percentage | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| Baseline -36 months | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| Baseline -24 months | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 87.5 (58.6 to 96.7) |
| Baseline -12 months | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 87.5 (58.6 to 96.7) |
| V2 (Baseline) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 87.5 (58.6 to 96.7) |
| V4 (Month 12) | 83.9 (49.4 to 95.7) | 80.0 (40.9 to 94.6) | 87.5 (58.6 to 96.7) |
| V6 (Month 24) | 83.9 (49.4 to 95.7) | 80.0 (40.9 to 94.6) | 87.5 (58.6 to 96.7) |
| V8 (Month 36) | 83.9 (49.4 to 95.7) | 80.0 (40.9 to 94.6) | 87.5 (58.6 to 96.7) |
This outcome measured the percentage of subjects without surgery or AAA rupture over time in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking.
| percentage | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| Baseline -36 months | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| Baseline -24 months | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| Baseline -12 months | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| V2 (Baseline) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| V4 (Month 12) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| V6 (Month 24) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
| V8 (Month 36) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
The incidence of open surgical AAA treatment or AAA endovascular repair and AAA rupture will be measured in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue to smoke CC and AAA patients who had stopped smoking. Incidence rate will be calculated annually.
| events per person-year | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| Number of patients with open surgical AAA treatment or endovascular repair annually | 0.05 | 0.05 | 0.05 |
| Number of patients with AAA rupture annually | 0.00 | 0.00 | 0.00 |
Incidence of AAA growth above 5 mm within 6 months will be measured in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking. Incidence rate will be calculated annually by counting the number of patients with an increase in maximum minor-axis AAA diameter of more than 5 mm within 6 months.
| events per person-year | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| Incidence of AAA Growth Above 5 mm Within 6 Months | 0 (0.0 to 0.2) | 0 (0.0 to 0.2) | 0 (0.0 to 0.2) |
The number of AAA patients with an overall maximum minor-axis AAA diameter \>55mm in male AAA patients and \>50mm in female AAA patients will be counted in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking. (Note that the 95% CI is calculated by exact method (Clopper-Pearson) and refers to CI for a proportion).
| participants | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| AAA Patients With an Overall Maximum Minor-axis AAA Diameter of >55mm in Male Patients and >50mm in Female Patients | 0 (0.0 to 0.2) | 0 (0.0 to 0.2) | 0 (0.0 to 0.2) |
This cardiovascular BoPH (systolic blood pressure) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
| mmHg | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| V1 (Screening) | 134.8 (126.6 to 143.0) | 128.0 (119.1 to 136.9) | 124.0 (117.1 to 130.9) |
| V2 (Baseline) | 132.5 (122.9 to 142.1) | 128.9 (120.1 to 137.8) | 135.9 (129.7 to 142.2) |
| V3 (Month 6) | 138.8 (129.0 to 148.6) | 131.1 (123.8 to 138.5) | 130.3 (121.5 to 139.0) |
| V4 (Month 12) | 132.7 (125.5 to 140.0) | 135.0 (128.5 to 141.5) | 129.3 (121.2 to 137.5) |
| V5 (Month 18) | 133.9 (125.9 to 141.9) | 130.6 (124.6 to 136.7) | 126.9 (120.0 to 133.9) |
| V6 (Month 24) | 136.6 (127.3 to 146.0) | 129.7 (120.7 to 138.7) | 128.1 (121.1 to 135.2) |
| V7 (Month 30) | 128.8 (121.1 to 136.5) | 136.1 (130.5 to 141.7) | 126.0 (114.1 to 137.9) |
| V8 (Month 36) | 131.7 (124.6 to 138.8) | 131.6 (126.2 to 137.1) | 125.3 (116.5 to 134.0) |
To measure nicotine exposure over time in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC, and AAA patients who had stopped smoking. (NEQ adjusted for creatinine (mg/g creat)).
| mg/g creat | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| V2 (Baseline) | 5.70 (4.22 to 7.72) | 6.30 (4.16 to 9.54) | 0 (0 to 0) |
| V3 (Month 6) | 5.13 (4.06 to 6.47) | 7.46 (5.39 to 10.32) | 0 (0 to 0) |
| V4 (Month 12) | 4.30 (2.43 to 7.61) | 5.50 (3.16 to 9.59) | 0 (0 to 0) |
| V5 (Month 18) | 5.86 (3.18 to 10.78) | 0.0 (0.0 to 0.0) | 0 (0 to 0) |
| V6 (Month 24) | 4.65 (2.70 to 8.02) | 4.32 (1.97 to 9.48) | 0 (0 to 0) |
| V7 (Month 30) | 3.88 (2.22 to 6.78) | 4.24 (1.98 to 9.07) | 0 (0 to 0) |
| V8 (Month 36) | 0 (0 to 0) | 4.20 (1.46 to 12.07) | 0 (0 to 0) |
This cardiovascular BoPH (diastolic blood pressure) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
| mmHg | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| V1 (Screening) | 75.4 (69.6 to 81.1) | 76.6 (71.0 to 82.2) | 72.9 (67.5 to 78.4) |
| V2 (Baseline) | 76.6 (70.5 to 82.6) | 76.6 (71.5 to 81.6) | 77.3 (73.0 to 81.5) |
| V3 (Month 6) | 79.7 (75.0 to 84.3) | 77.3 (73.4 to 81.2) | 73.9 (68.1 to 79.6) |
| V4 (Month 12) | 76.3 (70.5 to 82.2) | 77.3 (70.8 to 83.7) | 74.1 (68.0 to 80.1) |
| V5 (Month 18) | 74.8 (69.2 to 80.4) | 78.3 (72.4 to 84.2) | 71.5 (67.4 to 75.6) |
| V6 (Month 24) | 79.0 (74.3 to 83.7) | 78.5 (71.6 to 85.5) | 72.7 (68.3 to 77.1) |
| V7 (Month 30) | 76.3 (72.5 to 80.1) | 79.8 (73.9 to 85.6) | 69.2 (62.9 to 75.5) |
| V8 (Month 36) | 73.8 (68.0 to 79.5) | 77.8 (70.7 to 84.9) | 67.0 (61.5 to 72.5) |
This cardiovascular BoPH (body weight) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
| kg | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| V1 (Screening) | 68.44 (61.68 to 75.19) | 66.63 (60.48 to 72.78) | 67.91 (62.34 to 73.48) |
| V2 (Baseline) | 68.13 (61.51 to 74.75) | 66.61 (60.47 to 72.74) | 67.93 (62.39 to 73.47) |
| V3 (Month 6) | 67.79 (61.04 to 74.54) | 65.88 (60.00 to 71.76) | 67.98 (62.56 to 73.40) |
| V4 (Month 12) | 68.47 (61.53 to 75.42) | 66.51 (60.42 to 72.59) | 67.27 (61.38 to 73.16) |
| V5 (Month 18) | 69.41 (62.02 to 76.81) | 67.60 (61.22 to 73.98) | 66.70 (60.47 to 72.93) |
| V6 (Month 24) | 68.51 (62.41 to 74.61) | 67.82 (60.19 to 75.45) | 67.14 (61.06 to 73.21) |
| V7 (Month 30) | 67.61 (61.70 to 73.53) | 69.08 (61.79 to 76.38) | 66.03 (59.84 to 72.22) |
| V8 (Month 36) | 68.74 (62.36 to 75.12) | 69.71 (61.56 to 77.86) | 66.34 (59.61 to 73.08) |
This cardiovascular BoPH (waist circumference) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
| cm | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| V1 (Screening) | 90.51 (85.59 to 95.44) | 90.30 (85.11 to 95.49) | 91.40 (86.57 to 96.23) |
| V2 (Baseline) | 89.88 (84.61 to 95.14) | 91.01 (85.10 to 96.91) | 93.33 (88.80 to 97.85) |
| V3 (Month 6) | 89.95 (84.90 to 95.00) | 89.91 (84.06 to 95.75) | 91.16 (86.50 to 95.81) |
| V4 (Month 12) | 89.75 (84.17 to 95.34) | 89.46 (84.39 to 94.54) | 91.78 (86.74 to 96.82) |
| V5 (Month 18) | 91.73 (86.60 to 96.85) | 90.71 (84.99 to 96.42) | 91.82 (86.81 to 96.83) |
| V6 (Month 24) | 89.14 (81.91 to 96.36) | 91.55 (84.13 to 98.97) | 91.54 (86.91 to 96.16) |
| V7 (Month 30) | 89.04 (84.25 to 93.82) | 93.33 (86.51 to 100.16) | 91.43 (86.59 to 96.27) |
| V8 (Month 36) | 91.78 (87.65 to 95.90) | 92.30 (85.63 to 98.97) | 91.36 (85.93 to 96.79) |
This biomarker of exposure to a tobacco smoke constituent will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
| pg/mg creat | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| V2 (Baseline) | 124.09 (81.11 to 189.85) | 87.34 (55.98 to 136.27) | 0 (0 to 0) |
| V3 (Month 6) | 39.83 (17.74 to 89.41) | 108.70 (73.72 to 160.27) | 0 (0 to 0) |
| V4 (Month 12) | 27.12 (10.69 to 68.83) | 81.24 (52.33 to 126.12) | 0 (0 to 0) |
| V5 (Month 18) | 32.81 (12.77 to 84.33) | 61.85 (33.78 to 113.27) | 0 (0 to 0) |
| V6 (Month 24) | 33.02 (12.70 to 85.89) | 57.78 (31.17 to 107.11) | 0 (0 to 0) |
| V7 (Month 30) | 27.54 (10.09 to 75.21) | 61.78 (31.22 to 122.26) | 0 (0 to 0) |
| V8 (Month 36) | 35.24 (12.12 to 102.43) | 42.36 (15.30 to 117.29) | 0 (0 to 0) |
This biomarker of exposure to a tobacco smoke constituent will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
| pg/mg creatinine | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| V2 (Baseline) | 3.26 (1.78 to 5.97) | 2.09 (1.00 to 4.38) | 0 (0 to 0) |
| V3 (Month 6) | 1.39 (0.73 to 2.68) | 2.86 (1.61 to 5.09) | 0 (0 to 0) |
| V4 (Month 12) | 0.98 (0.42 to 2.30) | 2.12 (1.00 to 4.49) | 0 (0 to 0) |
| V5 (Month 18) | 1.28 (0.50 to 3.28) | 1.47 (0.54 to 4.00) | 0 (0 to 0) |
| V6 (Month 24) | 1.34 (0.51 to 3.52) | 1.55 (0.51 to 4.68) | 0 (0 to 0) |
| V7 (Month 30) | 1.20 (0.44 to 3.24) | 1.31 (0.50 to 3.48) | 0 (0 to 0) |
| V8 (Month 36) | 1.10 (0.37 to 3.27) | 1.27 (0.37 to 4.41) | 0 (0 to 0) |
This biomarker of exposure to a tobacco smoke constituent will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.
| ng/mg creat | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| V2 (Baseline) | 95.38 (71.93 to 126.48) | 98.95 (64.68 to 151.37) | 2.36 (1.36 to 4.10) |
| V3 (Month 6) | 20.21 (8.29 to 49.27) | 111.31 (74.30 to 166.76) | 1.67 (0.99 to 2.81) |
| V4 (Month 12) | 13.29 (4.61 to 38.34) | 82.46 (51.19 to 132.83) | 2.30 (1.10 to 4.80) |
| V5 (Month 18) | 12.53 (4.58 to 34.27) | 56.77 (26.94 to 119.63) | 1.70 (0.82 to 3.51) |
| V6 (Month 24) | 13.88 (4.22 to 45.68) | 48.40 (18.83 to 124.44) | 1.77 (0.77 to 4.06) |
| V7 (Month 30) | 8.25 (2.72 to 24.99) | 52.08 (20.21 to 134.23) | 1.51 (0.76 to 3.01) |
| V8 (Month 36) | 12.32 (3.31 to 45.91) | 46.19 (13.07 to 163.23) | 1.86 (0.92 to 3.77) |
Collected over Adverse events were collected from the signature of the ICF by each subject until the end of the safety follow-up period, a total duration for each subject of up to 37 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IQOS Arm | 1/16 (6.3%) | 3/16 (18.8%) | 14/16 (87.5%) |
| CC Arm | 1/16 (6.3%) | 5/16 (31.3%) | 13/16 (81.3%) |
| Smoking Cessation Arm | 0/16 (0%) | 7/16 (43.8%) | 14/16 (87.5%) |
| Event | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| Large intestine polypGastrointestinal disorders | 0/16 | 1/16 | 3/16 |
| Atrial fibrillationCardiac disorders | 2/16 | 0/16 | 0/16 |
| DeathGeneral disorders | 1/16 | 0/16 | 0/16 |
| Angina unstableCardiac disorders | 0/16 | 1/16 | 0/16 |
| Acute myocardial infarctionCardiac disorders | 0/16 | 0/16 | 1/16 |
| Angina pectorisCardiac disorders | 0/16 | 0/16 | 1/16 |
| Cardiac failureCardiac disorders | 0/16 | 0/16 | 1/16 |
| Myocardial ischaemiaCardiac disorders | 0/16 | 0/16 | 1/16 |
| CataractEye disorders | 0/16 | 1/16 | 0/16 |
| IleusGastrointestinal disorders | 0/16 | 0/16 | 1/16 |
| Event | IQOS Arm | CC Arm | Smoking Cessation Arm |
|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 2/16 | 2/16 | 4/16 |
| HypertensionsVascular disorders | 1/16 | 4/16 | 3/16 |
| Herpes zosterInfections and infestations | 1/16 | 1/16 | 3/16 |
| HyperuricaemiaMetabolism and nutrition disorders | 1/16 | 0/16 | 3/16 |
| Vision blurredEye disorders | 2/16 | 0/16 | 0/16 |
| ConstipationGastrointestinal disorders | 2/16 | 0/16 | 1/16 |
| GastritisGastrointestinal disorders | 0/16 | 0/16 | 2/16 |
| HaemorrhoidsGastrointestinal disorders | 0/16 | 0/16 | 2/16 |
| Large intestine polypGastrointestinal disorders | 0/16 | 1/16 | 2/16 |
| Oropharyngeal painGastrointestinal disorders | 0/16 | 0/16 | 2/16 |
| Age, Continuous(years) | IQOS Arm | CC Arm | Smoking Cessation Arm | Total |
|---|---|---|---|---|
| Mean | 71.0 ± 6.19 | 70.4 ± 7.73 | 71.3 ± 2.59 | 70.9 ± 5.79 |
| Sex: Female, Male(Participants) | IQOS Arm | CC Arm | Smoking Cessation Arm | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 16 | 16 | 16 | 48 |
| Race (NIH/OMB)(Participants) | IQOS Arm | CC Arm | Smoking Cessation Arm | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 16 | 16 | 16 | 48 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Nationality(Participants) | IQOS Arm | CC Arm | Smoking Cessation Arm | Total |
|---|---|---|---|---|
| Japanese | 16 | 16 | 16 | 48 |
| Other | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Apr 2023, 54 months.
Results were first posted in Aug 2025, 2 years 4 months after primary completion.
Of 56 industry-sponsored interventional studies with no phase under Smoking, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 54 months is above that.
Counting every sponsor, half of 461 studies reached it within 23 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.